Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005857 · ClinicalTrials.gov registry record · Phase 2
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
A Phase 2 study, sponsored by City of Hope Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00005857: Completed Phase 2 study, sponsored by City of Hope Medical Center.
NCT00005857 is a Phase 2 study that has completed, run by City of Hope Medical Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005857, a Phase 2 study, has completed, sponsored by City of Hope Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to compare the effectiveness of trastuzumab alone and in combination with docetaxel in treating patients who have metastatic prostate cancer that is refractory to hormone therapy.
Interventions
- DRUG docetaxel
- BIOLOGICAL trastuzumab
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-08 |
| Est. Completion | 2002-10 |
| Phase | Phase 2 |
What the finished NCT00005857 record still lists
NCT00005857 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 2 interventions - of which docetaxel is the first listed.
NCT00005857 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00005857 about?
NCT00005857 is a clinical study titled "Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy". RATIONALE: Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal...
What is the current status of trial NCT00005857?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-08. Estimated completion is 2002-10.
What interventions are being tested in trial NCT00005857?
The interventions under investigation include: docetaxel (DRUG), trastuzumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT00005857?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia